Oxford-developed.
Clinically validated.

Metabolomics is the large-scale study of small molecules (metabolites) present in biological samples such as blood. These molecules are the downstream products of every biochemical process in a living cell. They represent the immediate functional state of an organism, making the metabolome an exceptionally sensitive readout of health.

In human medicine, metabolomics has transformed diagnostics across oncology, cardiology, and metabolic disease. The technology has been used in landmark studies at the University of Oxford, Imperial College London, and leading centres worldwide.

SINO adapts this methodology for veterinary medicine, applying the same rigour and analytical depth to cats and dogs that the most advanced human diagnostic programmes bring to people.

Standard blood panels assess organ function through a small number of established biomarkers: enzymes, proteins, and cells. These markers typically change only once organ dysfunction is already advanced. By the time a conventional panel flags a problem, disease has often been developing silently for months or years.

Metabolomic changes occur far upstream of organ dysfunction, at the level of individual cells responding to stress, altered signalling, or early malignant transformation. This is why SINO can detect disease signatures that standard panels cannot see: the biochemical story of disease begins long before the clinical story.

The clinical significance of this lead time cannot be overstated. For many serious conditions, particularly cancer, early detection is the single most important factor determining treatment success and quality of life outcomes.

SINO integrates three complementary layers of biological data from a single blood sample:

Metabolomics: analysis of hundreds of small metabolites reflecting cellular metabolic activity and systemic health status.

Lipidomics: the complete lipid profile, including lipid species governing inflammation, immune function, and membrane integrity. Lipid dysregulation is an early marker of cardiovascular disease, cancer, and metabolic disorders.

Proprietary omics data: additional biological datasets developed by the LatusPet scientific team in collaboration with our partners at Oxford, capturing molecular signals not covered by standard published metabolomics panels.

The integration of these layers gives SINO a system-level view of health, not a snapshot of one pathway, but a comprehensive picture of cellular status across multiple biological dimensions simultaneously.

The complexity of multi-omics data is its greatest strength and its greatest analytical challenge. Hundreds of biomarkers, measured simultaneously, generate a data landscape far beyond the interpretive capacity of any individual reviewer or conventional statistical approach.

SINO addresses this through a proprietary AI and machine learning engine, trained on thousands of clinically annotated metabolomics profiles from cats and dogs. The model learns the molecular signatures associated with specific disease states, patterns that emerge only when hundreds of biomarkers are considered together, not in isolation.

Each validated SINO result contributes to the training dataset, creating a continuous learning loop. As the dataset grows, so does the precision and breadth of what SINO can detect. LatusPet is building what we believe to be the world's first proprietary veterinary metabolomics AI dataset, a compounding scientific asset with no equivalent in veterinary medicine.